Becton Dickinson and Company

BD makes essential medical devices and laboratory systems used across the healthcare ecosystem — from the needles and syringes used for blood draws and vaccinations, to sophisticated infusion pumps that deliver medications in hospitals, to diagnostic equipment that identifies infections in clinical labs [Yahoo Finance]. The company operates through four segments: Medical Essentials (basic supplies), Connected Care (infusion and medication management), BioPharma Systems (drug delivery devices for pharma companies), and Interventional and Life Sciences (surgical products and diagnostics) [Yahoo Finance].

Becton, Dickinson and Company (BDX) is a $40.5 billion global medical technology company that manufactures needles, syringes, laboratory equipment, infusion systems, and diagnostic products used in hospitals and clinics worldwide [Yahoo Finance]. The company recently reported solid Q2 earnings with 2.6% revenue growth to $4.7 billion, though underlying performance was stronger than headline numbers due to $1.3 billion in one-time charges [Yahoo Finance]. Despite financial strength, shares trade near historical lows and face headwinds from pressure in the Alaris infusion pump line, vaccines, and China operations [Yahoo Finance].

BD generates strong cash flow ($2.7 billion free cash flow) but carries elevated debt at 3.7x EBITDA, reflecting past M&A activity [Yahoo Finance].